Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING KIDNEY CANCER COMPRISING IFITM3 INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2024/096354
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating kidney cancer comprising an IFITM3 inhibitor. According to a composition according to one aspect, the tumorigenesis inhibitory effect can be induced by inhibiting the expression or activity of IFITM3. In particular, the pharmaceutical composition can inhibit the expression or activity of IFITM3 in treatment-resistant cancer cell lines to suppress tumorigenesis, tumor cell infiltration, and tumor cell survival, thereby effectively reducing treatment resistance. Accordingly, the pharmaceutical composition can be used to prevent or treat treatment-resistant cancer.
More Like This:
| JP7042254 | Near-infrared photocleavable conjugates and conjugate precursors |
| JP2010215644 | ANTIALLERGIC AGENT |
| WO/1994/004494 | TACHYKININ ANTAGONISTS |
Inventors:
CHO YONG-MEE (KR)
LEE JAE-LYUN (KR)
PARK JA MIN (KR)
YOON SUN YOUNG (KR)
LEE JAE-LYUN (KR)
PARK JA MIN (KR)
YOON SUN YOUNG (KR)
Application Number:
PCT/KR2023/015507
Publication Date:
May 10, 2024
Filing Date:
October 10, 2023
Export Citation:
Assignee:
ASAN FOUND (KR)
UNIV ULSAN FOUND IND COOP (KR)
UNIV ULSAN FOUND IND COOP (KR)
International Classes:
A61K31/404; A23L33/10; A61K31/4412; A61K31/4439; A61K31/47; A61K31/4709; A61K31/506; C12Q1/6886; G01N33/50; G01N33/68
Other References:
"Government Project Final Report", 17 May 2018, UNIVERSITY OF ULSAN, Korea, article CHO, YONG MEE: "Development of an integrative predictive model and identification of resistance mechanism of VEGF-targeted therapy in metastatic renal cell carcinoma", pages: 1 - 38, XP009554354
YING XU: "Overexpressing IFITM family genes predict poor prognosis in kidney renal clear cell carcinoma", TRANSLATIONAL ANDROLOGY AND UROLOGY, vol. 10, no. 10, 1 October 2021 (2021-10-01), pages 3837 - 3851, XP093166989, ISSN: 2223-4683, DOI: 10.21037/tau-21-848
YANG NANYAN; LIU ZHIHONG; PANG SHIYU; WU JINGJING; LIANG JUNGUANG; SUN LI: "Predicative value of IFITM2 in renal clear cell carcinoma: IFITM2 is associated with lymphatic metastasis and poor clinical outcome", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 534, 9 December 2020 (2020-12-09), Amsterdam NL , pages 157 - 164, XP086429373, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2020.11.124
CHENG SU: "Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers", FRONTIERS IN ONCOLOGY, FRONTIERS MEDIA S.A., vol. 11, 14 October 2021 (2021-10-14), XP093166991, ISSN: 2234-943X, DOI: 10.3389/fonc.2021.719564
PEI-YI CHU: "IFITM3 promotes malignant progression, cancer stemness and chemoresistance of gastric cancer by targeting MET/AKT/FOXO3/c-MYC axis", CELL & BIOSCIENCE, BIOMED CENTRAL LTD, LONDON, UK, vol. 12, no. 1, 1 January 2022 (2022-01-01), London, UK , XP093166992, ISSN: 2045-3701, DOI: 10.1186/s13578-022-00858-8
HEE SANG HWANG: "Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma", JOURNAL OF KOREAN MEDICAL SCIENCES, XMLINK, SEOUL, KR, vol. 35, no. 5, 1 January 2020 (2020-01-01), SEOUL, KR , XP093166993, ISSN: 1011-8934, DOI: 10.3346/jkms.2020.35.e31
YING XU: "Overexpressing IFITM family genes predict poor prognosis in kidney renal clear cell carcinoma", TRANSLATIONAL ANDROLOGY AND UROLOGY, vol. 10, no. 10, 1 October 2021 (2021-10-01), pages 3837 - 3851, XP093166989, ISSN: 2223-4683, DOI: 10.21037/tau-21-848
YANG NANYAN; LIU ZHIHONG; PANG SHIYU; WU JINGJING; LIANG JUNGUANG; SUN LI: "Predicative value of IFITM2 in renal clear cell carcinoma: IFITM2 is associated with lymphatic metastasis and poor clinical outcome", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 534, 9 December 2020 (2020-12-09), Amsterdam NL , pages 157 - 164, XP086429373, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2020.11.124
CHENG SU: "Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers", FRONTIERS IN ONCOLOGY, FRONTIERS MEDIA S.A., vol. 11, 14 October 2021 (2021-10-14), XP093166991, ISSN: 2234-943X, DOI: 10.3389/fonc.2021.719564
PEI-YI CHU: "IFITM3 promotes malignant progression, cancer stemness and chemoresistance of gastric cancer by targeting MET/AKT/FOXO3/c-MYC axis", CELL & BIOSCIENCE, BIOMED CENTRAL LTD, LONDON, UK, vol. 12, no. 1, 1 January 2022 (2022-01-01), London, UK , XP093166992, ISSN: 2045-3701, DOI: 10.1186/s13578-022-00858-8
HEE SANG HWANG: "Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma", JOURNAL OF KOREAN MEDICAL SCIENCES, XMLINK, SEOUL, KR, vol. 35, no. 5, 1 January 2020 (2020-01-01), SEOUL, KR , XP093166993, ISSN: 1011-8934, DOI: 10.3346/jkms.2020.35.e31
Attorney, Agent or Firm:
THEWAVE IP LAW FIRM (KR)
Download PDF: